Is ANIX or ZURA more profitable?

Zura Bio's return on equity of -56.13% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -76.59% -67.80% Zura Bio N/A -56.13% -50.15%

Does the media prefer ANIX or ZURA?

In the previous week, Anixa Biosciences had 1 more articles in the media than Zura Bio. MarketBeat recorded 3 mentions for Anixa Biosciences and 2 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.55 beat Anixa Biosciences' score of -0.57 indicating that Zura Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Zura Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANIX or KYTX more profitable?

Anixa Biosciences' return on equity of -76.59% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -76.59% -67.80% Kyverna Therapeutics N/A -81.92% -63.74%

Does the media prefer ANIX or ARCT?

In the previous week, Arcturus Therapeutics had 2 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 3 mentions for Anixa Biosciences. Arcturus Therapeutics' average media sentiment score of 0.99 beat Anixa Biosciences' score of -0.57 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Arcturus Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CCCC or ANIX?

In the previous week, C4 Therapeutics had 3 more articles in the media than Anixa Biosciences. MarketBeat recorded 6 mentions for C4 Therapeutics and 3 mentions for Anixa Biosciences. C4 Therapeutics' average media sentiment score of 0.68 beat Anixa Biosciences' score of -0.57 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Does the media favor ANIX or IRD?

In the previous week, Opus Genetics had 1 more articles in the media than Anixa Biosciences. MarketBeat recorded 4 mentions for Opus Genetics and 3 mentions for Anixa Biosciences. Opus Genetics' average media sentiment score of 0.73 beat Anixa Biosciences' score of -0.57 indicating that Opus Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Opus Genetics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Anixa Biosciences (ANIX) Competitors

$2.65 -0.02 (-0.75%)

As of 10/14/2026 04:00 PM Eastern

Compare

ANIX vs. ZURA, KYTX, ARCT, CCCC, and IRD

Should you buy Anixa Biosciences stock or one of its competitors? Anixa Biosciences's main competitors and comparable companies include Zura Bio (ZURA), Kyverna Therapeutics (KYTX), Arcturus Therapeutics (ARCT), C4 Therapeutics (CCCC), and Opus Genetics (IRD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Anixa Biosciences compare to Zura Bio?

Anixa Biosciences (NASDAQ:ANIX) and Zura Bio (NASDAQ:ZURA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Anixa Biosciences currently has a consensus target price of $8.00, suggesting a potential upside of 201.89%. Zura Bio has a consensus target price of $17.00, suggesting a potential upside of 285.49%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts clearly believe Zura Bio is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Zura Bio's return on equity of -56.13% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-76.59%	-67.80%
Zura Bio	N/A	-56.13%	-50.15%

In the previous week, Anixa Biosciences had 1 more articles in the media than Zura Bio. MarketBeat recorded 3 mentions for Anixa Biosciences and 2 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.55 beat Anixa Biosciences' score of -0.57 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by company insiders. Comparatively, 12.4% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Anixa Biosciences has higher revenue and earnings than Zura Bio. Anixa Biosciences is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	438.64	-$10.93M	-$0.32	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A

Anixa Biosciences has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Zura Bio has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market.

Summary

Zura Bio beats Anixa Biosciences on 9 of the 15 factors compared between the two stocks.

How does Anixa Biosciences compare to Kyverna Therapeutics?

Anixa Biosciences (NASDAQ:ANIX) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Anixa Biosciences' return on equity of -76.59% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-76.59%	-67.80%
Kyverna Therapeutics	N/A	-81.92%	-63.74%

In the previous week, Anixa Biosciences had 2 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 3 mentions for Anixa Biosciences and 1 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.89 beat Anixa Biosciences' score of -0.57 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Anixa Biosciences	Negative
Kyverna Therapeutics	Positive

Anixa Biosciences has higher revenue and earnings than Kyverna Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	438.64	-$10.93M	-$0.32	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A

Anixa Biosciences currently has a consensus target price of $8.00, suggesting a potential upside of 201.89%. Kyverna Therapeutics has a consensus target price of $29.00, suggesting a potential upside of 410.56%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kyverna Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Anixa Biosciences has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 2.06, indicating that its share price is 106% more volatile than the broader market.

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Anixa Biosciences and Kyverna Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Anixa Biosciences compare to Arcturus Therapeutics?

Anixa Biosciences (NASDAQ:ANIX) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Anixa Biosciences has higher earnings, but lower revenue than Arcturus Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	438.64	-$10.93M	-$0.32	N/A
Arcturus Therapeutics	$82.03M	3.85	-$65.78M	-$3.31	N/A

Anixa Biosciences presently has a consensus target price of $8.00, suggesting a potential upside of 201.89%. Arcturus Therapeutics has a consensus target price of $22.00, suggesting a potential upside of 97.84%. Given Anixa Biosciences' higher possible upside, equities analysts plainly believe Anixa Biosciences is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67

Anixa Biosciences has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-76.59%	-67.80%
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%

In the previous week, Arcturus Therapeutics had 2 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 3 mentions for Anixa Biosciences. Arcturus Therapeutics' average media sentiment score of 0.99 beat Anixa Biosciences' score of -0.57 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Arcturus Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Anixa Biosciences has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.48, indicating that its share price is 148% more volatile than the broader market.

Summary

Arcturus Therapeutics beats Anixa Biosciences on 10 of the 16 factors compared between the two stocks.

How does Anixa Biosciences compare to C4 Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Anixa Biosciences has a net margin of 0.00% compared to C4 Therapeutics' net margin of -289.44%. C4 Therapeutics' return on equity of -45.45% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-289.44%	-45.45%	-30.90%
Anixa Biosciences	N/A	-76.59%	-67.80%

C4 Therapeutics has a beta of 3.07, suggesting that its share price is 207% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

C4 Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 225.67%. Anixa Biosciences has a consensus target price of $8.00, indicating a potential upside of 201.89%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe C4 Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Anixa Biosciences has lower revenue, but higher earnings than C4 Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	8.93	-$104.99M	-$1.00	N/A
Anixa Biosciences	$210K	438.64	-$10.93M	-$0.32	N/A

In the previous week, C4 Therapeutics had 3 more articles in the media than Anixa Biosciences. MarketBeat recorded 6 mentions for C4 Therapeutics and 3 mentions for Anixa Biosciences. C4 Therapeutics' average media sentiment score of 0.68 beat Anixa Biosciences' score of -0.57 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Summary

C4 Therapeutics beats Anixa Biosciences on 10 of the 15 factors compared between the two stocks.

How does Anixa Biosciences compare to Opus Genetics?

Anixa Biosciences (NASDAQ:ANIX) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Anixa Biosciences has higher earnings, but lower revenue than Opus Genetics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	438.64	-$10.93M	-$0.32	N/A
Opus Genetics	$9.86M	34.38	-$49.59M	-$1.35	N/A

Anixa Biosciences has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

In the previous week, Opus Genetics had 1 more articles in the media than Anixa Biosciences. MarketBeat recorded 4 mentions for Opus Genetics and 3 mentions for Anixa Biosciences. Opus Genetics' average media sentiment score of 0.73 beat Anixa Biosciences' score of -0.57 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Opus Genetics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anixa Biosciences presently has a consensus target price of $8.00, indicating a potential upside of 201.89%. Opus Genetics has a consensus target price of $12.29, indicating a potential upside of 199.65%. Given Anixa Biosciences' higher possible upside, research analysts clearly believe Anixa Biosciences is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.89

Anixa Biosciences has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Opus Genetics' return on equity of 0.00% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-76.59%	-67.80%
Opus Genetics	-1,091.82%	N/A	-150.13%

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by insiders. Comparatively, 11.7% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Opus Genetics beats Anixa Biosciences on 9 of the 17 factors compared between the two stocks.

Get Anixa Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIX vs. The Competition

Export

Metric	Anixa Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$92.82M	$3.84B	$7.19B	$13.18B
Dividend Yield	N/A	3.65%	2.52%	19.60%
P/E Ratio	-8.28	9.48	211.42	19.26
Price / Sales	438.64	1,168.88	565.60	77.58
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	6.31	16.54	10.51	5.92
Net Income	-$10.93M	-$22.69M	$3.50B	$380.90M
7 Day Performance	-8.93%	-5.80%	-3.49%	-3.85%
1 Month Performance	-1.49%	-12.84%	-7.76%	-6.37%
1 Year Performance	-40.72%	3.05%	0.82%	-6.01%

Anixa Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIX Anixa Biosciences	3.0837 of 5 stars	$2.65 -0.7%	$8.00 +201.9%	-38.8%	$92.82M	$210K	N/A	4
ZURA Zura Bio	2.5007 of 5 stars	$4.18 +1.1%	$17.00 +307.2%	+23.2%	$400.09M	N/A	N/A	40
KYTX Kyverna Therapeutics	2.2842 of 5 stars	$6.45 +4.4%	$29.00 +349.6%	-16.0%	$398.89M	N/A	N/A	149
ARCT Arcturus Therapeutics	3.0584 of 5 stars	$13.89 +7.9%	$22.00 +58.4%	-47.7%	$394.47M	$82.03M	N/A	111	Gap Down
CCCC C4 Therapeutics	2.0578 of 5 stars	$3.12 +9.3%	$8.50 +172.9%	+29.2%	$383.22M	$35.04M	N/A	104	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIX) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anixa Biosciences (ANIX) Competitors

ANIX vs. ZURA, KYTX, ARCT, CCCC, and IRD

How does Anixa Biosciences compare to Zura Bio?

Summary

How does Anixa Biosciences compare to Kyverna Therapeutics?

Summary

How does Anixa Biosciences compare to Arcturus Therapeutics?

Summary

How does Anixa Biosciences compare to C4 Therapeutics?

Summary

How does Anixa Biosciences compare to Opus Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX vs. The Competition

Anixa Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anixa Biosciences (ANIX) Competitors

ANIX vs. ZURA, KYTX, ARCT, CCCC, and IRD

How does Anixa Biosciences compare to Zura Bio?

Do analysts prefer ANIX or ZURA?

Is ANIX or ZURA more profitable?

Does the media prefer ANIX or ZURA?

Do insiders & institutionals hold more shares of ANIX or ZURA?

Which has stronger valuation and earnings, ANIX or ZURA?

Which has more risk & volatility, ANIX or ZURA?

Summary

How does Anixa Biosciences compare to Kyverna Therapeutics?

Is ANIX or KYTX more profitable?

Does the media refer more to ANIX or KYTX?

Which has preferable earnings & valuation, ANIX or KYTX?

Do analysts prefer ANIX or KYTX?

Which has more risk and volatility, ANIX or KYTX?

Do institutionals and insiders hold more shares of ANIX or KYTX?

Summary

How does Anixa Biosciences compare to Arcturus Therapeutics?

Which has better valuation and earnings, ANIX or ARCT?

Do analysts recommend ANIX or ARCT?

Is ANIX or ARCT more profitable?

Does the media prefer ANIX or ARCT?

Do institutionals & insiders hold more shares of ANIX or ARCT?

Which has more volatility & risk, ANIX or ARCT?

Summary

How does Anixa Biosciences compare to C4 Therapeutics?

Is CCCC or ANIX more profitable?

Which has more risk & volatility, CCCC or ANIX?

Do institutionals and insiders have more ownership in CCCC or ANIX?

Do analysts rate CCCC or ANIX?

Which has stronger earnings and valuation, CCCC or ANIX?

Does the media favor CCCC or ANIX?

Summary

How does Anixa Biosciences compare to Opus Genetics?

Which has higher earnings and valuation, ANIX or IRD?

Which has more volatility and risk, ANIX or IRD?

Does the media favor ANIX or IRD?

Do analysts prefer ANIX or IRD?

Is ANIX or IRD more profitable?

Do institutionals & insiders have more ownership in ANIX or IRD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX vs. The Competition

Anixa Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools